蝙蝠葛碱对冠心病患者血小板聚集及血小板和血浆血栓素生成的影响

The Influences of Dauricin on Platelet Aggregation and Thromboxane Production of Platelet and Plasma in Patients with Coronary Heart Disease

观察蝙蝠葛碱对20例冠心病患者血小板聚集和血浆6-酮-前列腺素F_1a(6-Keto-PGF_1α)和血栓素B_2(TXB_2)生成的影响。结果表明:蝙蝠葛碱在体内外均能抑制冠心病患者的血小板聚集,其作用可能与抑制血小板TXA_2生成有关;蝙蝠葛碱还能抑制冠心病患者血浆TXA_2生成(服药前为339.80±15.99ng/L,服药后为147.17±10.11ng/L,P<0.01),而对6-Keto-PGF_1α生成无影响(服药前为148.50±7.98ng/L,服药后为156.75±10.33ng/L,P>0.05);并可使TXA_2-PGI_2平衡发生改变。

The influences of dauricin on platelet aggregation, production of plasma TXB2 and 6-keto-PGF1α in 20 patients with coronary heart disease (CHD) were observed. The results show that dauricin can inhibit platelet aggregation in vivo and in vitro in patients with coronary heart disease. It is also found that effects of dauricin inhibiting platelet aggregation were associated with decreased production of platelet TXA2. Dauricin can decrease production of plasma TXB2 (339.80±15.99 ng/L vs 147.17±10.11 ng/L, P<0.001) but has no effects on plasma 6-keto-PGF1α production (148.50±7.98 ng/L vs 156.75±10.33 ng/L, P>0.05). Thus TXA2-PGI2 equilibrium was altered. So we strongly incline to the view that dauricin might be of help to the treatment of patients with CHD.